Research > Biostatisticians
CRAB’s statistical team is comprised of biostatisticians with a wide variety of backgrounds and expertise. Our team has decades of experience in the field of cancer clinical and translational research, with specific expertise in designing, analyzing, reporting, and presenting important findings in the field of oncology. Drs. Hoering and Barlow have affiliate appointments at the Fred Hutchinson Cancer Research Center (heading the Myeloma and Breast Cancer Statistical Committees in SWOG) and the Biostatistics Department at the University of Washington. Dr. Crowley is the founder of CRAB and has an affiliate appointment at the School of Public Health at the Oregon Health and Science University.
Our clinical trial experience includes single- and multi-institution oncology trials, among them registrational trials, cooperative group SWOG trials, investigator-initiated trials and Phase I-IV industry sponsored trials. In addition to designing and analyzing trials, CRAB statisticians are involved with cutting-edge methodological research on novel clinical trial designs and high-dimensional data analysis, and have led or contributed to many publications, including the third edition of theHandbook of Statistics in Oncology Clinical Trialsco-edited by Drs. Crowley and Hoering.
Antje Hoering, Ph.D.
John Crowley, Ph.D.
William Barlow, Ph.D.
Katherine Nishimura, Ph.D.
Emily Goren, Ph.D.
Rachael Sexton, M.S.
Adam Rosenthal, M.S.
Dori Giroux, M.S.
Antje Hoering, Ph.D., President and Chief Executive Officer
is CEO, Chair and President of Cancer Research And Biostatistics (CRAB). She serves as the Consortium PI for the SWOG Computing and Data Management Center and the public-private LungMAP partnership. She is the lead statistician for the SWOG Myeloma Committee, an active member of the Myeloma Steering Committee and the Pediatric Lymphoma and Leukemia Committee for the National Clinical Trials Network. She is also an associate editor of the Statistics in Biopharmaceutical Research journal and co-editor of the third edition of the Handbook of Statistics in Clinical Oncology. Dr. Hoering has served as a faculty member for several national and international workshops instructing on biostatistical principles in oncology clinical trials, including for ASH Clinical Research Training Institute for the last few years. She has also served as a statistical consultant on various industry-sponsored trials, including a pivotal phase III registration trial in AML. Dr. Hoering serves as the Independent Analysis Center PI for a Friends of Cancer Research-sponsored collaboration (ctMoniTR) with leaders across multiple healthcare sectors and disciplines to investigate circulating tumor DNA as a potential monitoring tool to evaluate a patients response to treatment. Dr. Hoering holds affiliate appointments at the Fred Hutchinson Cancer Research Center and the Biostatistics Department of the University of Washington.
John Crowley, Ph.D., Chief of Strategic Alliances
brings four decades of experience in Biostatistics to his role as Chief of Strategic Alliances. He founded CRAB in 1997, and served as President and CEO until 2014. Dr. Crowley was the Director of the Statistical Center for SWOG, co-located at CRAB and the Fred Hutchinson Cancer Research Center, from 1984 to 2012. He is the author or co-author of over 400 scientific papers and books. Read more about John on our Management Team page.
William Barlow, Ph.D., Senior Biostatistician
is the lead statistician for the SWOG Breast Committee designing, conducting, and analyzing breast cancer clinical trials. In the latest study to be launched nationwide we will study whether the 21-gene recurrence assay can predict whether chemotherapy is beneficial in women with early stage node-positive, hormone receptor positive breast cancer. This study will include testing tumors in 9,000 women to identify 4,000 women who meet the requirements for the trial. Such biomarker evaluations can direct therapy – to this end he is involved in a grant with the Fred Hutchinson Cancer Research Center to develop methods for testing biomarkers in the clinical setting. Other interests include breast cancer screening, other clinical prognostic and predictive markers, trial design, and efficient sampling methods for biomarker evaluation.
Katherine Nishimura, Ph.D., Senior Biostatistician
received her MPH in Epidemiology and Biostatistics from the University of California, Berkeley, and her PhD in Epidemiology and Translational Science at the University of California, San Francisco. She has worked at CRAB since 2018 on the International Association for Study of Lung Cancer (IASLC), and is a member of the Pancreatic Cancer Research Team. Before joining CRAB, she worked at the National Institute of Allergy and Infectious Diseases studying clinical data in Mexico City influenza cases, and at the Fred Hutchinson Cancer Research Center conducting genome-wide association studies on inflammatory traits among US minorities.
Emily Goren, Ph.D., Senior Biostatistician
Dr. Goren received her PhD in Statistics from Iowa State University and her MS in Biostatistics from the University of Minnesota, Twin Cities. At CRAB, she has worked on the International Association for Study of Lung Cancer (IASLC) Thymic Epithelial Tumors Staging Project and the ctDNA to Monitor Treatment Response (ctMoniTR) Project. Prior to joining CRAB, she worked at Seagen, Microsoft, and the Institute for Health Metrics and Evaluation. Her experience includes: design and analysis of early phase clinical trials, CDISC standards, ChIP-seq and microbiome data analysis, and population forecasting. She has contributed to multiple open-source software packages for R and python.
Dori Giroux, M.S., Biostatistician
received her Master’s Degree from the University of Wisconsin-Madison and has over 25 years of experience as a biostatistician. She began her career at ICI Pharmaceuticals (now Astra Zeneca) in the therapeutic area of heart and hypertension. She joined the SWOG (Southwest Oncology Group) Statistical Center in 1992 and collaborated with Principal Investigators in the design and analysis of Phase I-III clinical trials in brain, breast, melanoma, lung and gynecologic cancers. Later, she served as a Project Director for a CRO (Clinical Research Organization) called SERC (Statistical and Epidemiologic Research Corporation), consulting with clients regarding clinical testing of new, proprietary agents in biotechnology Ms. Giroux has been employed at Cancer Research And Biostatistics (CRAB) as a Statistician since 1998. As a longstanding member of the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee, she has performed statistical analyses, data management, and project management for the IASLC Staging Projects in lung cancer, thymic malignancies, and mesothelioma since the inception of each of these projects.
Adam Rosenthal, M.S., Biostatistician
received his M.S. in Statistics from Arizona State University, and has worked at CRAB since 2012. He is experienced in the analysis of clinical trial data and outcome data, and the development of biomarkers based on high-dimensional data. He also has experience working with trial data meeting CDISC compliance regulations.
Rachael Sexton, M.S., Biostatistician
Rachael Sexton has worked with CRAB for over 12 years, providing her expertise in clinical trial design, protocol development, data safety monitoring, statistical analysis, and results reporting. Her clinical trial experience spans Phase I to Phase III trials, in both liquid and solid tumor settings, and she has co-authored nearly 20 publications in various journals, including the Lancet, the Lancet Haematology and JAMA. She currently serves as a statistician on the SWOG Myeloma Committee and is part the SWOG Latin America Initiative, supporting clinical trial development and contributing to clinical trial training courses. She also supports several of CRAB's Clinical Research Services (CRS) trials.